Nestlé Health Science has signed an exclusive agreement outside the United States and Canada for Seres Therapeutics’ novel class of microbiome therapeutics (Ecobiotics®) in the fields of Clostridium difficile infections and inflammatory bowel disease.
Through this agreement, Nestlé Health Science will support the potential future commercialization of the first ever microbiome therapy expected to be launched worldwide. SER 109 is in Phase 2 trials and targets multiple recurrent Clostridium difficile (C. diff), a bacterial infection that can affect the digestive system.
An additional C. diff and two inflammatory bowel disease (IBD) pipeline candidates are also part of the collaboration, including SER-287, the innovative microbiome therapeutic currently in Phase 1 clinical development in IBD.
Seres’ Ecobiotics® are first-in-field therapies, based upon microbial organisms and target the microbiome, the 100 trillion microorganisms that live within the human body. When unhealthy – or dysbiotic – the microbiome is increasingly understood to be causally related to a range of diseases.
Greg Behar, CEO of Nestlé Health Science and Seres Therapeutics Board member (pictured), said: “We are partnering with Seres, a clear leader in advancing their pipeline in the fast evolving microbiome field. We bring our worldwide footprint and capabilities in managing acute care and gastrointestinal (GI) related conditions through our diagnostics, nutritional solutions and innovative pipeline. Moreover, we bring our strong relationships with key opinion leaders, healthcare professionals and patient organizations as well as our experience in clinical development, regulatory and market access in IBD. Together with Seres Therapeutics, we will focus on successfully bringing this pipeline to patients and create innovative therapeutic approaches.”
Under the terms of the agreement, Nestlé Health Science will make an upfront payment of $120 million. Seres Therapeutics will be eligible to receive development and approval milestone payments totalling up to $660 million, and tiered single to double-digit royalties. The full potential value of the up-front payment, milestones and royalties payable by Nestlé Health Science is over $1.9 billion, assuming all products receive regulatory approval and significant revenue targets are met.
Seres Therapeutics will be responsible for all development costs associated with Phase 1 and Phase 2 for all four candidates as well as for Phase 3 for SER-109. Nestlé Health Science will participate with 33 per cent in the development costs associated with Phase 3 for three candidates (SER-262; SER-287, SER-301).